Dr. Bassel F. El-rayes, MD
Medical Oncology (Medical Oncology Physician)
200 W Arbor Dr
San Diego, CA 92103
Who else practices at this address →
San Diego County includes primary care (1% of residents) and mental health (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 30
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 59
Licensed in Alabama since 2022, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
CA license C206694 (first issued 2026; current) · GA license 062977 · MI license 4301069026 -
Hematology (Internal Medicine) Physician
CA license C206694 (first issued 2026; current) · MI license 4301069026 -
Hematology & Oncology Physician
AL license 44198 (first issued 2022; active) -
Internal Medicine Physician
MI license 4301069026
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Alabama Hospital Birmingham, AL
- UC San Diego Health Hillcrest - Hillcrest Med Ctr San Diego, CA
Medical groups
- University of Alabama Health Services Foundation, PC (2,814 clinicians)
- Regents of the University of California (2,089 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 59
- Services billed
- 267
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 131 | 54 |
| Established patient office or other outpatient visit, 20-29 minutes | 38 | 32 |
| New patient office or other outpatient visit, 60-74 minutes | 19 | 19 |
| New patient office or other outpatient visit, 45-59 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Oxycodone Hcl Other prescribers in San Diego, CA | 33 |
| Morphine Sulfate Er (morphine sulfate) Other prescribers in San Diego, CA | 18 |
| Amlodipine Besylate Other prescribers in San Diego, CA | 16 |
| Gabapentin Other prescribers in San Diego, CA | 16 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in San Diego, CA | 15 |
| Lorazepam Other prescribers in San Diego, CA | 15 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in San Diego, CA | 14 |
| Lonsurf (trifluridine/tipiracil hcl) | 14 |
| Afinitor (everolimus) | 13 |
| Promethazine Hcl Other prescribers in San Diego, CA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $2,538 in total to this clinician.
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2,538 |
|---|
| Consulting Fee | $2,538 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Aug 28, 2025 | Consulting Fee | $2,538 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $125,574 in research payments for these studies, mostly to the institutions running them.
- Phase Ib trial of pembrolizumab and XL888 in patients with advanced gastrointestinal malignancies
Merck Sharp & Dohme LLC - A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors ex…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.